Contact us 24/7

Onglyza

Diabetes Drug Onglyza Linked to Heart Injuries and Pancreatic Cancer

Thomas J. Henry is currently investigating reports of major cardiovascular events and pancreatic cancer in patients taking the diabetes drug Onglyza (saxagliptin.)

Sold under the trade names Onglyza and Kombiglyze XR, saxagliptin is an oral hypoglycemic developed by Bristol-Myers Squibb and AstraZeneca for the treatment of type 2 diabetes. According to various studies, however, treatment with saxagliptin can greatly increase a patient’s risk of suffering serious adverse events including heart failure, pancreatitis, and pancreatic cancer.

FDA INVESTIGATES REPORTS OF HEART RISKS LINKED TO SAXAGLIPTIN

In February 2014, the U.S. Food and Drug Administration announced that it was launching an investigation into the side effects of saxagliptin.

The FDA’s decision to do so came as a response to a study published in the New England Journal of Medicine which found that patients taking saxagliptin experienced a significant increase in their risk of suffering heart failure.

Risk of hospitalization for heart failure among patients taking saxagliptin increased by as much as 27 percent after treatment with the diabetes drug was initiated.

PREVIOUS DATA LINKS SAXAGLIPTIN TO PANCREATITIS AND PANCREATIC CANCER

In March of 2013, the FDA advised consumers that unpublished findings indicated that incretin mimetic drugs like saxagliptin may be linked to pancreatic duct metaplasia (pre-cancerous cellular changes) and pancreatitis.

While the FDA has yet to determine that saxagliptin can cause or contributes to the growth of pancreatic cancer, the regulatory agency has decided that the data warrants further investigation.

Other incretin mimetic drugs include:

  • Linagliptin (Tradjenta, Jentadueto)
  • Exenatide (Byetta, Bydureon)
  • Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync)
  • Liraglutide (Victoza)
  • Alogliptin (Nesina, Kazano, Oseni)

HAVE YOU BEEN INJURED?

If you’ve been injured, we can help. Contact us